Anaptysbio (ANAB) Receivables - Net (2016 - 2026)

Anaptysbio (ANAB) has 10 years of Receivables - Net data on file, last reported at $25.7 million in Q1 2026.

• Quarterly Receivables - Net rose 43.97% year-over-year to $25.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.7 million (up 43.97% YoY) and the FY2025 annual result came in at $33.8 million, down 16.96% from the prior year.
• Receivables - Net fell to $25.7 million in Q1 2026, from $33.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $75.7 million in Q3 2025 to a low of $921000.0 in Q1 2022.
• A 5-year average of $15.5 million and a median of $7.1 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net dropped 26.14% — and 2025, when it jumped 520.62%.
• Tracing ANAB's Receivables - Net over 5 years: stood at $1.4 million in 2022, then soared by 382.8% to $6.9 million in 2023, then soared by 495.02% to $40.8 million in 2024, then fell by 16.96% to $33.8 million in 2025, then retreated by 23.94% to $25.7 million in 2026.
• The last three Receivables - Net figures came in at $25.7 million (Q1 2026), $33.8 million (Q4 2025), and $75.7 million (Q3 2025), per Business Quant data.